Innocrin Receives European Union Financial Breaks to Help It Continue Developing Prostate Cancer Therapy

Innocrin Receives European Union Financial Breaks to Help It Continue Developing Prostate Cancer Therapy
The European Medicines Agency has granted small and medium-sized enterprise status to Innocrin Pharmaceuticals, a designation that provides the company with financial incentives to continue developing its prostate cancer therapy seviteronel (VT-464). Seviteronel (VT-464) treats an aggressive form of the disease known as castration-resistant prostate cancer (CRPC). It inhibits CYP17 lyase, an enzyme involved in the production of male hormones known as androgens and female hormones known as estrogens. It also blocks the androgen receptors that attract androgens. Both of seviteronel's roles are important because prostate cancer cannot gr
Subscribe or to access all post and page content.

2 comments

Leave a Comment

Your email address will not be published. Required fields are marked *